RxDoctor Payments Data

Hannah James, MD

Internal Medicine · Punta Gorda, FLNPI 1407219454

Payments from drug & device makers

$1,684in general payments, 2019–2025

Across 52 payments — averaging $32.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$699
  • Amgen$327
  • Boston Scientific$126
  • AbbVie$98
  • Novo Nordisk$63
  • Novartis$60
  • plus $310 from 14 others

What the payments were for

  • Consulting fees$69942%
  • Food & beverage$98558%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,684 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$237,605
Medicare patients
654
Services billed
5,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$136,915
EliquisApixaban55$85,051
TrulicityDulaglutide38$50,556
MounjaroTirzepatide36$47,167
XareltoRivaroxaban27$28,801
JardianceEmpagliflozin14$20,577
Repatha SureclickEvolocumab13$17,456
JanuviaSitagliptin Phosphate11$13,610
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,311
Levothyroxine Sodium428$5,180
Omeprazole192$3,353
Rosuvastatin Calcium217$3,186
Fenofibrate19$3,139
SynthroidLevothyroxine Sodium47$2,652
Testosterone Cypionate56$2,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$63$136,91595 claims
Lilly USA, LLCTrulicity, Mounjaro$37$97,72274 claims
PfizerEliquis$14$85,05155 claims
GSKTrelegy Ellipta$12$13,31115 claims
AbbVieSynthroid$98$2,65247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Punta Gorda

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →